Daito Pharmaceutical Co.,Ltd. (TYO:4577)
Japan
· Delayed Price · Currency is JPY 1,260.00
-5.00 (-0.40%)
Apr 28, 2026, 3:30 PM JST
Daito Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is June - May.
Millions JPY. Fiscal year is Jun - May.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Feb '26 Feb 28, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 | May '21 May 31, 2021 | 2020 - 2016 |
| Revenue | 50,766 | 50,643 | 46,895 | 45,101 | 43,464 | 48,714 | Upgrade
|
| Revenue Growth (YoY) | 3.94% | 7.99% | 3.98% | 3.77% | -10.78% | 8.28% | Upgrade
|
| Cost of Revenue | 41,387 | 42,005 | 37,056 | 34,770 | 32,005 | 37,922 | Upgrade
|
| Gross Profit | 9,379 | 8,638 | 9,839 | 10,331 | 11,459 | 10,792 | Upgrade
|
| Selling, General & Admin | 5,874 | 3,333 | 3,431 | 3,082 | 3,004 | 2,719 | Upgrade
|
| Research & Development | - | 2,520 | 2,349 | 1,865 | 1,749 | 2,032 | Upgrade
|
| Operating Expenses | 5,874 | 6,017 | 5,945 | 5,119 | 4,891 | 4,876 | Upgrade
|
| Operating Income | 3,505 | 2,621 | 3,894 | 5,212 | 6,568 | 5,916 | Upgrade
|
| Interest Expense | -134 | -123 | -41 | -12 | -9 | -8 | Upgrade
|
| Interest & Investment Income | 70 | 64 | 65 | 57 | 55 | 64 | Upgrade
|
| Earnings From Equity Investments | 88 | 75 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 10 | 34 | -23 | -91 | 22 | 66 | Upgrade
|
| Other Non Operating Income (Expenses) | 26 | 33 | 29 | 4 | 93 | 28 | Upgrade
|
| EBT Excluding Unusual Items | 3,565 | 2,704 | 3,924 | 5,170 | 6,729 | 6,066 | Upgrade
|
| Gain (Loss) on Sale of Investments | 331 | 409 | 326 | -87 | 47 | 1 | Upgrade
|
| Asset Writedown | -154 | -384 | -165 | -17 | -56 | -314 | Upgrade
|
| Other Unusual Items | -4 | 228 | 134 | 11 | - | 120 | Upgrade
|
| Pretax Income | 3,816 | 2,957 | 4,219 | 5,077 | 6,720 | 5,873 | Upgrade
|
| Income Tax Expense | 872 | 1,192 | 1,040 | 1,549 | 2,092 | 1,716 | Upgrade
|
| Earnings From Continuing Operations | 2,944 | 1,765 | 3,179 | 3,528 | 4,628 | 4,157 | Upgrade
|
| Minority Interest in Earnings | 14 | 143 | 116 | 72 | 40 | 89 | Upgrade
|
| Net Income | 2,958 | 1,908 | 3,295 | 3,600 | 4,668 | 4,246 | Upgrade
|
| Net Income to Common | 2,958 | 1,908 | 3,295 | 3,600 | 4,668 | 4,246 | Upgrade
|
| Net Income Growth | 36.13% | -42.09% | -8.47% | -22.88% | 9.94% | 7.66% | Upgrade
|
| Shares Outstanding (Basic) | 30 | 30 | 31 | 32 | 31 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 30 | 30 | 31 | 32 | 31 | 30 | Upgrade
|
| Shares Change (YoY) | -1.83% | -3.06% | -0.86% | 3.38% | 1.94% | 6.42% | Upgrade
|
| EPS (Basic) | 99.47 | 62.72 | 105.00 | 113.82 | 152.45 | 141.36 | Upgrade
|
| EPS (Diluted) | 99.47 | 62.72 | 105.00 | 113.71 | 152.45 | 141.36 | Upgrade
|
| EPS Growth | 40.24% | -40.27% | -7.67% | -25.41% | 7.85% | 1.16% | Upgrade
|
| Free Cash Flow | - | -892 | -1,038 | -1,350 | -257 | -1,136 | Upgrade
|
| Free Cash Flow Per Share | - | -29.32 | -33.08 | -42.65 | -8.39 | -37.82 | Upgrade
|
| Dividend Per Share | 37.500 | 35.000 | 30.000 | 27.273 | 22.727 | 20.909 | Upgrade
|
| Dividend Growth | 15.38% | 16.67% | 10.00% | 20.00% | 8.70% | 15.00% | Upgrade
|
| Gross Margin | 18.48% | 17.06% | 20.98% | 22.91% | 26.36% | 22.15% | Upgrade
|
| Operating Margin | 6.90% | 5.17% | 8.30% | 11.56% | 15.11% | 12.14% | Upgrade
|
| Profit Margin | 5.83% | 3.77% | 7.03% | 7.98% | 10.74% | 8.72% | Upgrade
|
| Free Cash Flow Margin | - | -1.76% | -2.21% | -2.99% | -0.59% | -2.33% | Upgrade
|
| EBITDA | - | 6,953 | 7,553 | 9,082 | 9,881 | 9,070 | Upgrade
|
| EBITDA Margin | - | 13.73% | 16.11% | 20.14% | 22.73% | 18.62% | Upgrade
|
| D&A For EBITDA | 4,837 | 4,332 | 3,659 | 3,870 | 3,313 | 3,154 | Upgrade
|
| EBIT | 3,505 | 2,621 | 3,894 | 5,212 | 6,568 | 5,916 | Upgrade
|
| EBIT Margin | 6.90% | 5.17% | 8.30% | 11.56% | 15.11% | 12.14% | Upgrade
|
| Effective Tax Rate | 22.85% | 40.31% | 24.65% | 30.51% | 31.13% | 29.22% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.